30 TECHNOLOGY: REALISING THE FULL POTENTIAL OF THERAPEUTIC NITRIC OXIDE

Advancing NO Innovation: ConvaNiox Approved

A big congratulations to the Convatec team on the regulatory approval of ConvaNiox – a major milestone for nitric oxide-based wound care.

30 Technology Enrolls First Patient in Pioneering NOPA Trial for New Inhaled Antimicrobial RESP303

30 Technology is excited to announce that on October 16, 2024, the first patient was enrolled into the NOPA study.

30 Technology announces interim results from Phase 2 tuberculosis trial

30 Technology is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA).

30 TECHNOLOGY is developing nitric oxide-generating technologies for a range of health care applications

Watch Video